Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Oramed Pharmaceuticals Inc. before investing.

In this article, we go over a few key elements for understanding Oramed Pharmaceuticals Inc.’s stock price such as:

• Oramed Pharmaceuticals Inc.’s current stock price and volume
• Why Oramed Pharmaceuticals Inc.’s stock price changed recently
• Upgrades and downgrades for ORMP from analysts
• ORMP’s stock price momentum as measured by its relative strength

About Oramed Pharmaceuticals Inc. (ORMP)

Before we jump into Oramed Pharmaceuticals Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company’s product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Want to learn more about Oramed Pharmaceuticals Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Oramed Pharmaceuticals Inc..

Oramed Pharmaceuticals Inc.’s Stock Price as of Market Close

As of February 11, 2025, 4:00 PM, CST, Oramed Pharmaceuticals Inc.’s stock price was $2.600.

Oramed Pharmaceuticals Inc. is up 19.82% from its previous closing price of $2.170.

During the last market session, Oramed Pharmaceuticals Inc.’s stock traded between $2.230 and $3.090. Currently, there are approximately 40.90 million shares outstanding for Oramed Pharmaceuticals Inc..

Oramed Pharmaceuticals Inc.’s price-earnings (P/E) ratio is currently at 19.9, which is low compared to the Pharmaceuticals industry median of 19.9. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Oramed Pharmaceuticals Inc. Stock Price History

Oramed Pharmaceuticals Inc.’s (ORMP) price is currently up 16.07% so far this month.

During the month of February, Oramed Pharmaceuticals Inc.’s stock price has reached a high of $3.090 and a low of $2.120.

Over the last year, Oramed Pharmaceuticals Inc. has hit prices as high as $3.670 and as low as $2.000. Year to date, Oramed Pharmaceuticals Inc.’s stock is up 7.44%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Oramed Pharmaceuticals Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of February 10, 2025,, no analysts have changed their rating of Oramed Pharmaceuticals Inc.’s stock over the last month.

Additionally, you'll want to evaluate Oramed Pharmaceuticals Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Oramed Pharmaceuticals Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Oramed Pharmaceuticals Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Oramed Pharmaceuticals Inc. (ORMP) by visiting AAII Stock Evaluator.

Relative Price Strength of Oramed Pharmaceuticals Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of February 10, 2025, Oramed Pharmaceuticals Inc. has a weighted four-quarter relative price strength of -9.74%, which translates to a Momentum Score of 26 and is considered to be Weak.

Want to learn more about how Oramed Pharmaceuticals Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Oramed Pharmaceuticals Inc. Stock Price: Bottom Line

As of February 11, 2025, Oramed Pharmaceuticals Inc.’s stock price is $2.600, which is up 19.82% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Oramed Pharmaceuticals Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.